Prosecution Insights
Last updated: November 20, 2026
Application No. 17/792,670

CONSORTIA OF MICROORGANISMS FOR SPATIAL AND TEMPORAL DELIVERY OF NITROGEN

Final Rejection §101
Filed
Jul 13, 2022
Priority
Jan 13, 2020 — provisional 62/960,655 +2 more
Examiner
JONES-FOSTER, ERICA NICOLE
Art Unit
1656
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pivot Bio Inc.
OA Round
3 (Final)
50%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
46 granted / 91 resolved
-9.5% vs TC avg
Strong +38% interview lift
Without
With
+37.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
61 currently pending
Career history
162
Total Applications
across all art units

Statute-Specific Performance

§101
8.2%
-31.8% vs TC avg
§103
37.8%
-2.2% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
24.9%
-15.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 91 resolved cases

Office Action

§101
DETAILED CORRESPONDENCE Application Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants’ amendment to the claims filed on 8/19/2026 is acknowledged and entered into the record. Support for the amendments is within the instant application specification. Applicant’s amendment to the claims filed on 8/19/2026 in response to the Non-Final Rejection mailed on 6/2/2026 is acknowledged. This listing of claims replaces all prior listings of claims in the application. Claims 1-2, 5-6, 10, 13, 26, 29, 37, 43, 47-50, 58-59, 70, 74-75 are pending. Claims 3-4, 7-9, 11-12, 14-25, 27-28, 30-36, 38-42, 44-46, 51-57, 60-69, 71-73, 76-118 are canceled. Claim 70, 74-75 stand withdrawn pursuant to 37 CFR 1.142(b). Claims 1-2, 5-6, 10, 13, 26, 29, 37, 43, 47-50, 58-59 are pending and examined on the merits. Applicants’ remarks filed on 8/19/2026 in response to the Non-Final Rejection mailed on 6/2/2026 have been fully considered and found to be persuasive to overcome the rejections and/or objections of record. The text of those sections of Title 35 U.S. Code not included in the instant action can be found in the prior Office Action. Information Disclosure Statement The information disclosure statement (IDS) submitted on 8/21/2026 is acknowledged. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the Examiner. Maintained Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The rejection of claims 1-2, 5-6, 10, 13, 26, 29, 37, 43, 47-50, 58-59 under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter is maintained. The rejection has been modified in view of Applicant’s amendment of claim 1 to recite ‘d) spatial occupation, wherein at least one of the nitrogen fixing microbes in the consortium is not genetically engineered and at least one of the nitrogen fixing microbes in the consortium is a Klebsiella variicola deposited as ATCC PTA-126740 or a Kosakonia sacchari deposited as ATCC PTA-126743, each of which is genetically engineered to de-repress nitrogen fixation.’ The claims do not fall within at least one of the four categories of patent eligible subject matter because the claimed invention is a naturally occurring microorganism. Step 1: Is the claim to a process, machine, manufacture or composition of matter? Yes, the claim is drawn to a composition of matter, which is one of the four statutory categories. Step 2, Prong One: Does the claim recite an abstract idea, law of nature, or natural phenomenon? Yes, the claim is directed to a natural phenomenon (product of nature). Said natural phenomenon is a composition of microbes. Claims 1-2, 5-6, 10, 13, 26, 29, 37, 43, 47-50, 58-59 are directed towards (synthetic) composition of microbes comprising: a consortium of at least two nitrogen fixing microbes that differ in functional attributes along at least one of the following dimensions: a) nutrient utilization ; b) temporal occupation; c) oxygen adaptability; and d) spatial occupation, wherein at least one of the nitrogen fixing microbes in the consortium is not genetically engineered and at least one of the nitrogen fixing microbes in the consortium is a Klebsiella variicola deposited as ATCC PTA-126740 or a Kosakonia sacchari deposited as ATCC PTA-126743, each of which is genetically engineered to de-repress nitrogen fixation. In the broadest reasonable interpretation of the claim, Applicants have not clearly argued as to how the claimed composition is “markedly different” from such microorganisms, especially the natural microbes which form part of the composition occurring individually by themselves. There is no evidence that the microbes exhibit any markedly different characteristics when used separately vs as a composition. The recitation of said microbial species being ‘non-intergeneric remodeled bacterium’ (Instant Application Specification para 0137) does not provide enough information that would overcome the rejection as the term ‘remodeled’ is broad and could be naturally occurring. Applicant is reminded that the claims are read in-light of the specification. The claims must stand alone. Thus, the mixture does not have markedly different characteristics from what occurs in nature, and is a “product of nature” exception. Just by mixing genetically modified microorganisms with naturally occurring microorganisms does not make the naturally occurring microbes “markedly different” in any way compared to them occurring in the natural state. If there were any such “markedly different” characteristics, such characteristics has not been demonstrated or explained by the applicant. Step 2A, Prong Two: Does the claim recite additional elements that integrate the judicial exception into a practical application? Claims 1, 5-6, 10, 13, 26, 29, 37 include the additional element of differing in functional attributes along at least one of the following dimensions: a) nutrient utilization; b) temporal occupation; c) oxygen adaptability; and d) spatial occupation. Such a limitation is native to the bacterium. Therefore, it does not integrate the judicial exception into a practical application for the same reasons discussed above. Furthermore, additional elements of the synthetic composition comprising at least one of the nitrogen fixing microbes in the consortium is a Klebsiella variicola deposited as ATCC PTA-126740 or a Kosakonia sacchari deposited as ATCC PTA-126743 do not integrate the judicial exception into a practical application as Applicant has not provided any explanation in their remarks or within the claim language as to if and how said microbes render the naturally occurring microbes in the composition “markedly different” compared to when used separately. Step 2B: Does the claim recite additional elements that amount to significantly more than the judicial exception? No. The judicial exception is recited without additional limitations amounting to significantly more than the exception. All of the signified additional elements to the judicial exception are considered to be native to the bacteria on which the judicial exception is to be performed as noted in Step 2A, Prong 2, and, therefore, do not amount to significantly more than the judicial exception that is claimed because the claim does not include any additional features that could add significantly more to the exception. In reference to claim 1 of Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 131 (1948), which recites ‘an inoculant for leguminous plants comprising a plurality of selected mutually non-inhibitive strains of different species of bacteria of the genus Rhizobium, said strains being unaffected by each other in respect to their ability to fix nitrogen in the leguminous plant for which they are specific,’ the inoculant of claim 1 was held to be ineligible subject matter. Discovery of the fact that certain strains of each species of these bacteria can be mixed without harmful effect to the properties of either is a discovery of their qualities of non-inhibition. It is no more than the discovery of some of the handiwork of nature and hence is not patentable. The aggregation of select strains of the several species into one product is an application of that newly-discovered natural principle. But however ingenious the discovery of that natural principle may have been, the application of it is hardly more than an advance in the packaging of the inoculants. Each of the species of root-nodule bacteria contained in the package infects the same group of leguminous plants which it always infected. No species acquires a different use. The combination of species produces no new bacteria, no change in the six species of bacteria, and no enlargement of the range of their utility. Each species has the same effect it always had. The bacteria perform in their natural way. Their use in combination does not improve in any way their natural functioning. They serve the ends nature originally provided and act quite independently of any effort of the patentee. Recently, the Supreme Court looked back to this claim as an example of ineligible subject matter, stating that “the composition was not patent eligible because the patent holder did not alter the bacteria in any way.” Myriad, 133 S. Ct. at 2117. In this regard, as the instant claims recite judicial exceptions that are not integrated into practical application, and no elements that amount to significantly more than the judicial exception as recited, the claims were found not to be drawn to eligible subject matter under 35 U.S.C. 101 as the combination of ‘synthetic composition of microbes’ produces no new bacteria and no changes in the claimed bacteria. Each species has the same effect it always had. The bacteria perform in their natural way. Their use in combination does not improve in any way their natural functioning. They serve the ends nature originally provided and act quite independently of any effort of the patentee. RESPONSE TO REMARKS: Applicant's arguments filed 8/19/2026 have been fully considered but they are not persuasive. Beginning on p. 7 of Applicants’ remarks, Applicants in summary contends that the claimed consortium of nitrogen fixing bacteria comprises at least one genetically engineered microbe and, thus, said composition is not naturally occurring. The argument is not persuasive. Examiner contends that Applicants have not shown how the combination of the genetically modified microbes and natural occurring microbes makes the naturally occurring microbes “markedly different” in their characteristics compared to before mixing them with genetically modified microbes. Or in other words, one of the genetically engineered microbe listed in claim 1 that is not seen when either one of the natural microbe or the genetically modified microbe is used separately that can be considered as “markedly different” characteristics. It is recommended that Applicant provide scientific argument to the contrary. . Conclusion Status of claims Claims 1-2, 5-6, 10, 13, 26, 29, 37, 43, 47-50, 58-59 are pending and examined on the merits. Claims 3-4, 7-9, 11-12, 14-25, 27-28, 30-36, 38-42, 44-46, 51-57, 60-69, 71-73, 76-118 are canceled. Claim 70, 74-75 stand withdrawn pursuant to 37 CFR 1.142(b). Claims 1-2, 5-6, 10, 13, 26, 29, 37, 43, 47-50, 58-59 are rejected. No claims are in conditions of allowance. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERICA NICOLE JONES-FOSTER whose telephone number is (571)270-0360. The examiner can normally be reached mf 7:30a - 4:30p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Manjunath Rao can be reached at 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERICA NICOLE JONES-FOSTER/ Examiner, Art Unit 1656 /MANJUNATH N RAO/ Supervisory Patent Examiner, Art Unit 1656
Read full office action

Prosecution Timeline

Jul 13, 2022
Application Filed
Sep 11, 2025
Non-Final Rejection mailed — §101
Mar 11, 2026
Response Filed
Jun 02, 2026
Non-Final Rejection mailed — §101
Aug 21, 2026
Response Filed
Oct 30, 2026
Final Rejection mailed — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781203
ATP-INDEPENDENT BIOLUMINESCENT REPORTER VARIANTS TO IMPROVE IN VIVO IMAGING
5y 2m to grant Granted Nov 03, 2026
Patent 12643927
ENGINEERED SPIDER SILK PROTEINS AND USES THEREOF
3y 9m to grant Granted Jun 02, 2026
Patent 12600761
METHODS AND COMPOSITIONS FOR PURIFICATION OF TRIMERIC FUSION PROTEINS
3y 1m to grant Granted Apr 14, 2026
Patent 12594308
METHODS OF PREPARING A POSTBIOTIC COMPOSITION
1y 6m to grant Granted Apr 07, 2026
Patent 12590291
METHOD OF INDUCING EXPRESSION OF CALCIUM CHANNEL AND/OR CALCIUM PUMP, AND APPARATUS THEREFOR
3y 11m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
50%
Grant Probability
88%
With Interview (+37.7%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 91 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month